Reviewing Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) & Suzuki Motor (OTCMKTS:SZKMY)

Suzuki Motor (OTCMKTS:SZKMY) and Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) are both auto/tires/trucks companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Institutional and Insider Ownership

0.0% of Suzuki Motor shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Suzuki Motor and Recordati Industria Chimica e Farmaceutica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Suzuki Motor	4.62%	8.65%	4.92%
Recordati Industria Chimica e Farmaceutica	18.51%	31.80%	12.83%

Risk & Volatility

Suzuki Motor has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Recordati Industria Chimica e Farmaceutica has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Suzuki Motor and Recordati Industria Chimica e Farmaceutica, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Suzuki Motor	0	0	1	0	3.00
Recordati Industria Chimica e Farmaceutica	0	1	0	0	2.00

Earnings & Valuation

This table compares Suzuki Motor and Recordati Industria Chimica e Farmaceutica’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Suzuki Motor	$34.36 billion	0.66	$1.64 billion	$3.45	13.42
Recordati Industria Chimica e Farmaceutica	$1.95 billion	N/A	$329.08 million	$1.93	26.74

Suzuki Motor has higher revenue and earnings than Recordati Industria Chimica e Farmaceutica. Suzuki Motor is trading at a lower price-to-earnings ratio than Recordati Industria Chimica e Farmaceutica, indicating that it is currently the more affordable of the two stocks.

Summary

Suzuki Motor beats Recordati Industria Chimica e Farmaceutica on 7 of the 11 factors compared between the two stocks.

About Suzuki Motor

Suzuki Motor Corporation engages in the manufacturing and marketing of automobiles, motorcycles, and marine products in Japan, rest of Asia, Europe, North America, and internationally. It offers mini-vehicles, sub-compact vehicles, standard-sized vehicles, outboard motors, motorized wheelchairs, and electro senior vehicles. The company is also involved in solar power generation and logistics business, as well as provides other services. Suzuki Motor Corporation was founded in 1909 and is headquartered in Hamamatsu, Japan.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.